Publication Title: 
PloS One

BACKGROUND: Glioma, including anaplastic astrocytoma and glioblastoma multiforme (GBM) are among the most commonly diagnosed malignant adult brain tumors. GBM is a highly invasive and angiogenic tumor, resulting in a 12 to 15 months median survival. The treatment of GBM is multimodal and includes surgical resection, followed by adjuvant radio-and chemotherapy. We have previously reported that short-term starvation (STS) enhances the therapeutic index of chemo-treatments by differentially protecting normal cells against and/or sensitizing tumor cells to chemotoxicity.

Safdie, Fernando
Brandhorst, Sebastian
Wei, Min
Wang, Weijun
Lee, Changhan
Hwang, Saewon
Conti, Peter S.
Chen, Thomas C.
Longo, Valter D.
Publication Title: 

To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications.

Kast, Richard E.
Boockvar, John A.
Brüning, Ansgar
Cappello, Francesco
Chang, Wen-Wei
Cvek, Boris
Dou, Q. Ping
Duenas-Gonzalez, Alfonso
Efferth, Thomas
Focosi, Daniele
Ghaffari, Seyed H.
Karpel-Massler, Georg
Ketola, Kirsi
Khoshnevisan, Alireza
Keizman, Daniel
Magné, Nicolas
Marosi, Christine
McDonald, Kerrie
Muñoz, Miguel
Paranjpe, Ameya
Pourgholami, Mohammad H.
Sardi, Iacopo
Sella, Avishay
Srivenugopal, Kalkunte S.
Tuccori, Marco
Wang, Weiguang
Wirtz, Christian R.
Halatsch, Marc-Eric
Publication Title: 

CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs--aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one or more important growth-enhancing pathways used by glioblastoma. By blocking survival paths, the aim is to render temozolomide, the current standard cytotoxic drug used in primary glioblastoma treatment, more effective.

Kast, Richard E.
Karpel-Massler, Georg
Halatsch, Marc-Eric
Publication Title: 
PloS One

Glioblastoma stem cells (GSC) are a significant cell model for explaining brain tumor recurrence. However, mechanisms underlying their radiochemoresistance remain obscure. Here we show that most clonogenic cells in GSC cultures are sensitive to radiation treatment (RT) with or without temozolomide (TMZ). Only a few single cells survive treatment and regain their self-repopulating capacity.

Ye, Fei
Zhang, Yibei
Liu, Yue
Yamada, Kazunari
Tso, Jonathan L.
Menjivar, Jimmy C.
Tian, Jane Y.
Yong, William H.
Schaue, Dörthe
Mischel, Paul S.
Cloughesy, Timothy F.
Nelson, Stanley F.
Liau, Linda M.
McBride, William
Tso, Cho-Lea
Publication Title: 
Ai Zheng = Aizheng = Chinese Journal of Cancer

BACKGROUND AND OBJECTIVE: Epigenetic silencing of the DNA repair gene, O6-methylguanine-DNA methyltransferase (MGMT), is associated with the therapeutic response to methylating agents. This study was to assess the value of detecting the promoter methylation of MGMT gene in chemotherapy for glioma. METHODS: Methylation-specific PCR (MSP) was employed to detect MGMT promoter CpG island methylation in 39 samples of glioma taken from surgery. Western blot and immunohistochemistry were used to detect protein expression.

Zheng, Chang-Qing
Ji, Shou-Ping
Gong, Feng
Li, An-Ming
Tai, Jun-Li
Zhang, Yang-Pei
Publication Title: 
Journal of Child Neurology

Gliomatosis confined to the cerebellum is most unusual. We report such a case in a 20-month-old male who presented with unsteadiness. Magnetic resonance imaging revealed a diffuse area of abnormal signal intensity within both cerebellar hemispheres, which did not enhance after contrast administration. The patient underwent a biopsy, which revealed a diffuse glioma infiltrating the cerebellum. Overall, the tumor cells had oligodendroglioma-like features and exhibited only focal vimentin immunoreactivity.

Chadarévian, Jean-Pierre de
Legido, Agustin
Halligan, Gregory E.
Faerber, Eric N.
Piatt, Joseph H.
Morrissette, Jennifer D.
Ara, Jahan
Grant, Mitzie L.
Katsetos, Christos D.
Subscribe to RSS - Dacarbazine